IHE - Fund Research and Flow
iShares U.S. Pharmaceuticals ETF (IHE) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $696.5M, listed on AMEX, carrying a beta of 0.57 to the broader market. The iShares U. public since 2006-05-05.
iShares U.S. Pharmaceuticals ETF (IHE) is an exchange-traded fund. Sell-side equity analyst coverage at the fund level is uncommon: ETFs are usually evaluated via fund-research methodologies (asset allocation, factor exposure, expense ratio, tracking error, premium / discount to NAV) rather than the EPS-and-price-target framework applied to operating companies. The relevant research surface for an ETF is fund-flow data, holdings-overlap analysis, and total-return performance attribution.
- Exchange
- AMEX
- Sector
- Financial Services
- Industry
- Asset Management
- Market Cap
- $696.5M
- IPO Date
- 2006-05-05
- Beta
- 0.57
How ETF Fund Flows Inform Trading
Fund flows (creations and redemptions) shift the supply of ETF shares and the demand for the underlying basket. Persistent inflows force authorized participants (APs) to create new shares, driving demand for the constituent basket; persistent outflows force redemptions and supply the basket. Flow-induced basket activity affects single-name liquidity, intraday price impact, and the implied-volatility surface on heavily-held constituents. Funds tracking thematic or factor indices typically show flow-driven concentration that magnifies these effects.
How IHE Options Track Fund Mechanics
For options traders, the relevant per-ETF inputs are the chain liquidity, dealer gamma exposure, and the implied-volatility relationship between the ETF and its constituents. ETF IV typically sits below the weighted-average constituent IV because of the diversification benefit (correlations below one), and the magnitude of that compression is itself a tradable signal. Compare IHE implied volatility against top-holding single-name IVs, and watch IHE gamma exposure to see how dealer hedging on the ETF chain interacts with index-replication arbitrage by APs.
Learn how analyst ratings is reported and how to read the data →
Frequently asked IHE analyst ratings questions
- What ETF research applies to IHE?
- iShares U.S. Pharmaceuticals ETF (IHE) is an exchange-traded fund, so sell-side equity analyst coverage at the fund level is uncommon. ETFs are evaluated via fund-research methodologies: asset allocation and factor exposure, expense ratio versus peers, average daily volume as a chain-liquidity proxy, tracking error against the underlying index, and the time series of premium and discount to NAV. The relevant research surface is fund-flow data, holdings-overlap analysis, and total-return performance attribution rather than the price-target framework.
- How do IHE fund flows drive trading?
- Fund flows (creations and redemptions) shift the supply of ETF shares and the demand for the underlying basket. Persistent inflows force authorized participants to create new shares, driving demand for the constituent basket; persistent outflows force redemptions and supply the basket. Flow-induced basket activity affects single-name liquidity, intraday price impact, and the implied-volatility surface on heavily-held constituents. Thematic and factor ETFs typically show flow-driven concentration that magnifies these effects on their largest holdings.
- How does IHE options pricing relate to constituent IV?
- ETF implied volatility typically sits below the weighted-average constituent implied volatility because of the diversification benefit (constituent correlations below one compress aggregate vol). The magnitude of that compression is itself a tradable signal: the dispersion trade pays out when realized correlation among constituents diverges from the implied correlation embedded in the IV wedge. Compare IHE IV against top-holding single-name IVs on the volatility page to read this relationship.
- Where can I find IHE holdings and fund-flow data?
- Daily holdings are typically published on the sponsor's site for transparent ETFs (most are). Aggregate fund-flow figures by category and product live on FINRA reporting and third-party flow trackers. SEC EDGAR carries the formal disclosures: N-CSR semi-annual and annual shareholder reports, N-PX annual proxy-voting records, and N-CEN annual census filings. The sponsor's investor-relations page typically links the latest holdings file alongside the regulatory documents.